Mgr. Jan Smetana, Ph.D.
Researcher II, Section of Genetics and Molecular Biology
office: bldg. C03/333
Kamenice 753/5
625 00 Brno
phone: | +420 549 49 7640 |
---|---|
e‑mail: |
Total number of publications: 88
2016
-
Detection of oncogenic mutations in cervical carcinoma using method "High Resolution Melting" (HRM).
Neoplasma, year: 2016, volume: 63, edition: 5, DOI
-
Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance
European Journal of Haematology, year: 2016, volume: 97, edition: 6, DOI
-
Whole genome amplification effect on segmental copy-number changes and copy-number neutral loss of heterozygosity analysis by oligonucleotide-array based comparative genomic hybridization in human myeloma cell line
International Journal of Clinical and Experimental Pathology, year: 2016, volume: 9, edition: 7
2015
-
Molecular cytogenetic analyses of hTERC (3q26) and MYC (8q24) genes amplifications in correlation with oncogenic human papillomavirus infection in Czech patients with cervical intraepithelial neoplasia and cervical carcinomas
Neoplasma, year: 2015, volume: 62, edition: 1, DOI
-
První zkušenosti s preimplantačním genetickým screeningem chromozomových abnormalit pomocí komparativní genomové hybridizace na oligonukleotidových DNA mikročipech
Časopis lékařů českých, year: 2015, volume: 154, edition: 3
2014
-
Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience
BioMed Research International, year: 2014, volume: Neuveden, edition: MAY, DOI
-
Genome-wide screening of DNA copy number alterations in cervical carcinoma patients with CGH+SNP microarrays and HPV-FISH
International Journal of Clinical and Experimental Pathology, year: 2014, volume: 7, edition: 8
-
Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH
Neoplasma, year: 2014, volume: 61, edition: 1, DOI
2013
-
Effect of DNA Dosage into Gene Expression in Patients with Multiple Myeloma
Year: 2013, type: Conference abstract
-
Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
Clinical lymphoma, myeloma & leukemia, year: 2013, volume: 13, edition: 2, DOI